Drug intelligence / Profile preview

polymerized Dermatophagoides pteronyssinus allergoid

Development stage
Unknown
Lead developer
Laboratorios Diater
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Intradermal
01

Overview

Polymerized Dermatophagoides pteronyssinus allergoid is an allergen immunotherapy (AIT) product developed by Diater Laboratorio de Diagnósticos y Aplicaciones Terapéuticas, S.A. It consists of an allergenic extract derived from the house dust mite *Dermatophagoides pteronyssinus* that has been chemically modified through polymerization with glutaraldehyde. This polymerization process is intended to reduce the allergenicity (IgE-binding capacity) of the native extract, thereby enhancing safety by minimizing the risk of systemic allergic reactions, while preserving its immunogenicity to induce a protective immune response. The drug is primarily indicated for the treatment of allergic rhinoconjunctivitis and mild-to-moderate allergic asthma associated with house dust mite sensitization. It is administered via the intradermal route and has been investigated in Phase 2 clinical trials to confirm the maximum non-reactive dose and evaluate safety in sensitized adults.

Other names
polymerized D. pteronyssinusglutaraldehyde-polymerized Dermatophagoides pteronyssinus extract
02

Targets

Der p 2 (Dermatophagoides pteronyssinus allergen 2)Der p 1 (Dermatophagoides pteronyssinus allergen 1)

Beyond the preview

Go deeper on polymerized Dermatophagoides pteronyssinus allergoid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on polymerized Dermatophagoides pteronyssinus allergoid.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call